This reference contains FDA-approved drug label information, including warnings and precautions, drug interactions, and full-color images of some drugs. Every label includes information on dosages, side effects, and safety information, such as contraindications, pregnancy ratings, and interactions with other drugs, food, or alcohol.
With a new preface outlining the most recent critical developments, this updated edtion of The Future of the Professions predicts how technology will transform the work of doctors, teachers, architects, lawyers, and many others in the 21st century, and introduces the people and systems that may replace them.
This book describes seven areas in the field of biotechnology operations as practiced by biopharmaceutical firms and nonprofit institutions. Revisions focus upon changes that have occurred in several areas over the past six years, with emphasis on regulatory, biomanufacturing, clinical and technical information, along with processes and guidlines that have added to the discipline. Examples are increased for new technical fields such as cell and tissue engineering. Further, illustrations or figures are added to each chapter to emphasize particular points.
• Describes regulatory testing requirements for all the major classes of marketed products • Explains how to prepare required documents for mandated safety testing of product • Features new chapters addressing Safety Data Sheet Preparation and Regulatory Requirements for GMOs • Covers Safety Data Sheet Preparation, which has replaced the Material Safety Data Sheet system
The American Psychiatric Association Publishing Textbook of Psychopharmacology is an indispensable and comprehensive resource for clinicians and trainees who prescribe psychotropic medications. Updated to reflect the new DSM-5 classification, this revised Fifth Edition maintains the user-friendly structure of its predecessors while offering in-depth coverage of the latest research in pharmacological principles, classes of drugs, and psychiatric disorders. Introductory chapters provide a theoretical grounding in clinical applications, with topics ranging from neurotransmitters to brain imaging in psychopharmacology. The bulk of the book is devoted to various classes of drugs, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, and other agents, with each class divided into chapters on specific drugs -- either new or revised to include the latest findings and trends. Finally, the section on psychopharmacological treatment addresses evidence-based principles of clinical care for the full spectrum of mental disorders and conditions -- from depression to chronic pain -- as well as for specific populations and circumstances -- from children and adolescents to psychiatric emergencies -- offering information on topics such as medication selection, combination and maintenance dosing regimens, monitoring and management of side effects, and strategies for optimizing treatment response. The book's beneficial features are many: The section on principles of pharmacology has been revised and reorganized to incorporate recent discoveries from the fields of neurobiology, genetics, brain imaging, and epidemiology. History and discovery, structure--activity relationships, pharmacological profiles, pharmacokinetics and disposition, mechanisms of action, indications and efficacy, side effects and toxicology, and drug--drug interactions are addressed for each agent. This consistent structure places the desired information at the clinician's fingertips and facilitates study for trainees. Coverage of drugs approved since the last edition is thorough, encompassing new antidepressants (e.g., vortioxetine), new antipsychotics (e.g., cariprazine), and agents on the clinical horizon (e.g., ketamine). More than 180 tables and graphs present critically important data in an accessible way. A work of uncommon scientific rigor and clinical utility, The American Psychiatric Association Publishing Textbook of Psychopharmacology provides state-of-the-art information on both the principles and the practice of psychopharmacological treatment of psychiatric disorders.
This practical guide presents a road map for safety assessment as an integral part of the development of new drugs and therapeutics. Helps readers solve scientific, technical, and regulatory issues in preclinical safety assessment and early clinical drug development Explains scientific and philosophical bases for evaluation of specific concerns – including local tissue tolerance, target organ toxicity and carcinogenicity, developmental toxicity, immunogenicity, and immunotoxicity Covers the development of new small and large molecules, generics, 505(b)(2) route NDAs, and biosimilars Revises material to reflect new drug products (small synthetic, large proteins and cells, and tissues), harmonized global and national regulations, and new technologies for safety evaluation Adds almost 20% new and thoroughly updates existing content from the last edition
Advances in Treatment of Bipolar Disorders provides clinicians with a well-written and timely guide to the most recent advances in the treatment of patients with this complex disorder. Staying abreast of new research developments and treatment options presents a daunting challenge, but the editor and coauthors have compiled the most important evidence-based findings from controlled studies and U.S. Food and Drug Administration approved indications, facilitating integration of these findings into clinical practice. This volume strives to provide clinicians with the necessary information to enable them to balance the likelihood of benefit (using “number needed to treat” analyses) versus harm (using “number needed to harm” analyses) in order to provide individualized, state-of-the-art, evidence-based care. The most current research findings are complemented by the authors’ extensive personal clinical experiences, resulting in a volume that reflects the most up-to-date thinking about the diagnosis and management of bipolar disorder. Advances in Treatment of Bipolar Disorders belongs in every mental health clinician’s library.
As the baby boomer generation becomes senior citizens and starts to flood into the last stage of life, a new definition and new expectations of retirement and aging are evolving. This is not your father’s way of being an older adult. People today tend not to retire in a traditional way. They envision getting older as a challenge to stay active and engaged, a chance to reinvent themselves, and an opportunity to reach for new goals. However, for some, this stage of life can be difficult, bringing with it a whole range of new challenges and obstacles. Along the way, many may deal with mental health problems such as stress and anxiety, grief and depression, drug and alcohol abuse, changes in marital and other relationships, as well as elder abuse. Are you ready? How will you fill your new free time? How will you cope with the psychological changes? Let this book, on coping with the emotional, mental, physical, and spiritual issues of retirement and aging from a psychiatrist’s perspective, light the way. This book will help readers deal with common issues across a broad spectrum. It offers treatment options, suggests coping skills, and even deals with spiritual and emotional challenges at the end of life. It will help you invest in relationships, redefine your marriage, and broaden your horizons. It will allow you to take charge of your life in retirement and not just let it happen to you.
This reference contains FDA-approved drug label information, including warnings and precautions, drug interactions, and full-color images of some drugs. Every label includes information on dosages, side effects, and safety information, such as contraindications, pregnancy ratings, and interactions with other drugs, food, or alcohol.
